Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy

Table 1 Patient clinical characteristics

Patient	Age at baseline (years)/sex	Diagnosis	Cytogenetics	Induction	Consolidation	Remission status	Weeks since end of chemotherapy	Baseline ALC (/cu mm)
AML 01	67/F	M5	trisomy 8, inv(16)	AcIVP16	HiDAc × 1	CR1	49	1660
AML 02	69/F	MDS to AML	46 XX	7 + 3	Moderate dose Ac	CR1	10	750
AML 03	52/M	N/A	46 XY, NPM1+	FLAM	FLAM	CR1	45	2530
AML 04	48/F	N/A	inv(16)	AcDVP16	HiDAc × 4	CR1	19	810
AML 05	28/F	N/A	46 XX	AcDVP16	AcDAc	CR1	26	1860
AML 06	58/M	N/A	t(8;21)	AcDVP16	HiDAc × 1, AcDAc	CR1	148	2710
AML 07	55/M	M5	46 XY, FLT3-D835+, NPM1+	AcDVP16	HiDAc × 4	CR1	31	1160
AML 08	66/M	M5	46 XY, NPM1+	AcDVP16	HiDAc × 4	CR1	8	650
AML 09	63/M	M4	46 XY, NPM1+	FLAM	FLAM	CR1	34	730
AML 10	28/M	M3 (APL)	t(15;17), FLT3-ITD+	ATRA/D	AcDArsenic	CR1	4	1440

AML subtype under diagnosis defined by the French–American–British (FAB) classification of AML. MDS myelodysplastic syndrome, APL acute promyelocytic leukemia, ITD internal tandem duplication, NPM1 nucleophosmin, FLT3 fms-like tyrosine kinase, ITD internal tandem duplication, CR1 first complete remission, ALC absolute lymphocyte count. A/Ac cytarabine, I idarubicin, VP16 etoposide, FL flavoperidol, M mitoxantrone, D daunorubicin, ATRA all trans retinoic acid, HiD high dose

ISSN: 1479-5876